Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study.

ABSTRACT:

Context

Growth hormone (GH) is prescribed for an increasing range of indications, but there has been concern that it might raise cancer risk. Published data are limited.

Objective

To examine cancer risks in relation to GH treatment.

Design

Cohort study.

Setting

Population-based.

Patients

Cohort of 23,984 patients treated with recombinant human GH (r-hGH) in eight European countries since this treatment was first used in 1984. Cancer expectations from country-specific national population statistics.

Main outcome measures

Cancer incidence and cancer mortality.

Results

Incidence and mortality risks in the cohort were raised for several cancer sites, largely consequent on second primary malignancies in patients given r-hGH after cancer treatmen

SUBMITTER: Swerdlow AJ 

PROVIDER: S-EPMC6061931 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature